BPC-157

What it is

BPC-157 is a synthetic 15-amino-acid peptide based on a fragment of a protein found in human gastric juice. It was developed largely by Predrag Sikirić's group at the University of Zagreb, which has published most of the research on it. Unlike most peptides it is reported to be stable in stomach acid.

How it works

The exact receptor is unknown. Animal and cell studies point to increased blood-vessel growth (VEGFR2 signaling), activation of nitric oxide pathways, faster migration of tendon cells and protection of the gut lining.

What the research shows

• Hundreds of rodent studies report faster healing of tendon, ligament, muscle, bone and gut injuries.
• Human evidence is very thin: a small pilot study of injections for knee pain and early trials of an oral form for inflammatory bowel disease, none large or controlled enough to establish benefit or safety.
• Because research comes mostly from one group, independent replication is an open question.

Regulatory status

Not FDA-approved. In 2023 the FDA listed BPC-157 among bulk substances raising potential safety concerns for compounding. In July 2026 the FDA's Pharmacy Compounding Advisory Committee voted 8 to 6 to recommend adding it to the list pharmacies may compound. On October 28, 2026, the Department of Health and Human Services announced an interim enforcement discretion policy covering BPC-157 and five other peptides: it does not intend to take action against state-licensed pharmacies, federal facilities or licensed physicians that compound them under section 503A, as long as strict conditions are met. These include bulk material from an FDA-registered manufacturer with a certificate of analysis, a single active ingredient, only the routes of administration the policy lists, specific labeling and reporting of serious adverse events to the FDA. The policy does not add BPC-157 to the 503A bulks list or approve any product, it does not cover 503B outsourcing facilities, and HHS says it may revisit the policy if safety or quality problems arise. Research-grade material is not a compounded drug product. It is prohibited in sport by the World Anti-Doping Agency.

Storage and handling

Lyophilized (freeze-dried) powder is most stable sealed, dry and protected from light. Laboratory practice is to keep unopened vials frozen at about -20 °C for long-term storage, or refrigerated at 2 to 8 °C for shorter periods. After reconstitution, keep the solution refrigerated at 2 to 8 °C, avoid repeated freeze-thaw cycles and use aseptic technique for every draw. Formal stability data in solution has not been published for most research peptides, so follow the supplier's label and certificate of analysis.

Reconstitution math

To work out concentration, volume and U-100 syringe units for any vial size, use the reconstitution calculator with BPC-157 selected. Always confirm the vial content against the label and the batch's certificate of analysis.

Key references

• Sikirić P and colleagues, University of Zagreb: review articles on BPC-157 and tissue healing, 2010 to 2024.
• AJMC. FDA panel backs 6 peptides for compounding. July 2026.
• Search PubMed for BPC-157 studies

Found in these blends

Related compounds